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1 Abstract (233 words)
2
3 Objective: Dilated cardiomyopathy (DCM) has been documented in Cocker Spaniels. 
4 American Cocker Spaniels (ACS) with taurine deficiency and DCM phenotype 
5 improved following taurine supplementation. No studies have been performed 
6 investigating taurine deficiency in English Cocker Spaniels (ECS). The aims of this 
7 study were to evaluate taurine levels in ECS with DCM and assess their survival time 
8 and natural progression of their disease.
9
10 Methods: Retrospective comparison of ECS with DCM phenotype with and without 
11 taurine deficiency at the cardiology department of a UK academic referral centre 
12 between 2008 and 2018. 
13
14 Results: Taurine plasma concentration was available in 16 ECS with DCM 
15 phenotype; 13/16 of which had congestive heart failure and 3/16 of which did not. 
16 Taurine concentration was low (<50 μmol/L) in 13/16 and normal in 3/16. Deficient 
17 dogs received taurine supplementation in addition to conventional cardiac 
18 medications. Eight dogs were still alive at the end of this study and 8 were dead. 
19 MST for all dogs included in the study was 2800 days. Left ventricular (LV) systolic 
20 function improved and LV dimensions reduced in ECS with taurine deficiency 
21 following taurine supplementation and conventional cardiac therapy, although similar 
22 results were observed in ECS with normal taurine concentration on cardiac therapy 
23 alone. 
24
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25 Clinical importance: Based on laboratory reference intervals, low taurine 
26 concentrations were common in ECS with DCM, showing a possible association 
27 between DCM in ECS and taurine deficiency; supplementation with taurine was not 
28 curative. 
29
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34 Dilated cardiomyopathy (DCM) is the most common acquired myocardial disease in 
35 dogs (Fox et al. 1999). Echocardiography is the gold standard for diagnosis: 
36 decreased systolic function leads to renin-aldosterone-angiotensin system (RAAS) 
37 activation and ventricular dilation which may eventually result in congestive heart 
38 failure. Left atrial enlargement and arrhythmias may also be present (Dukes-McEwan 
39 et al. 2003). The preclinical or occult phase of the disease is characterized by 
40 chamber dilation with reduced systolic function and possible arrhythmias with no 
41 clinical signs (Dukes-McEwan et al. 2003). Medical treatment varies depending on 
42 the phase. Pimobendan is recommended for occult DCM (Summerfield et al. 2012), 
43 but once clinical signs of CHF develop, addition of diuretics and potentially ACE 
44 inhibitors and spironolactone, is indicated (Dukes-McEwan 2000; Luis Fuentes et al. 
45 2002). Any haemodynamically significant arrhythmias may also require treatment.
46
47 Primary (idiopathic) DCM has been documented in a number of breeds including 
48 English cocker spaniel (ECS) (Gooding et al. 1982, 1986; Thomas 1987; Tidholm et 
49 al. 1997). In a large UK survey of dogs presenting with DCM, ECS was the fourth 
50 most common breed affected, with 30/369 cases and was reported to have longer 
51 survival times compared with other breeds (Martin et al. 2009).
52
53 The DCM phenotype may be a consequence of heritable genetic mutations, viral 
54 infections, immune-mediated disorders, arrhythmias, toxins and nutritional 
55 deficiencies (Van Vleet and Ferrans, 1986; Cunningham et al., 1992; Shinbane et al., 
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56 1997; Backus et al. 2006). Due to familial disease, a genetic basis is suspected in 
57 some breeds and already documented in others, including ECS (Thomas 1987), as 
58 recently reviewed by Dutton & Lopez-Alvarez (2018). Prior to making the diagnosis 
59 of DCM, other conditions which may result in similar echocardiographic changes 
60 must be actively excluded.
61
62 Taurine deficiency has been implicated as a nutritional cause of a DCM phenotype. 
63 This was initially reported in a group of cats affected by DCM, where the phenotype 
64 completely reversed with taurine supplementation; prior to this discovery, the 
65 prognosis for cats with DCM caused by taurine deficiency was grave (Pion et al. 
66 1987). Later, American Cocker Spaniels (ACS) with low taurine concentrations were 
67 also reported to at least partially reverse their DCM phenotype after both taurine and 
68 L-carnitine supplementation (Kittleson et al. 1997). Other studies reported similar 
69 findings, in this and other breeds such as Golden Retrievers (Kramer et al., 1995; 
70 Gavaghan & Kittleson 1997; Kaplan et al., 2018; Ontiveros et al., 2020).  
71
72 English cocker spaniels were imported into the United States in the 19th century: 
73 ACS were developed and eventually recognized as a different breed in 1936 (Fogle 
74 1996). Therefore, there is likely to be a genetic relationship between the ACS studied 
75 by Kittleson and colleagues (1997) and the ECS population. To the authors’ 
76 knowledge, no studies have been reported investigating taurine deficiency in ECS 
77 with DCM.  
78
79 The main aim of this study was to investigate a possible association between taurine 
80 deficiency and DCM in ECS in the UK.  The hypothesis was that ECS with a 
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81 diagnosis of DCM could also have low taurine levels, similar to ACS. Additional aims 
82 of this study were to investigate the response to taurine supplementation in deficient 
83 ECS and document the progression of DCM and survival times in this breed. 
84
85 Materials and methods
86 This was an observational, retrospective study. Cases were retrieved from a single 
87 multidisciplinary referral hospital in the UK. 
88 The hospital database was searched for ECS examined by the cardiology service 
89 between 2008 and 2018 and diagnosed with DCM. Dogs were included if retrieved 
90 data included both a complete echocardiographic examination and plasma taurine 
91 concentration. All dogs had indirect assessment of systolic blood pressure (Doppler 
92 method). Routine blood work (haematology, biochemistry, thyroid function 
93 assessment) was carried out if the clinician considered it relevant to the 
94 investigations for each patient.
95
96 Dogs with other concurrent cardiac conditions were excluded. Dogs with clinical 
97 signs, blood pressure or clinical pathology results indicating significant systemic 
98 disease, including systemic hypertension, were excluded. Systemic hypertension 
99 was defined as >160mmHg on repeated measurements on more than one occasion, 
100 in accordance with the ACVIM guidelines (Acierno et al. 2018). 
101 Dogs affected by hypothyroidism, on treatment with levothyroxine, were included 
102 provided that the dog had been receiving treatment for over 2 months prior to 
103 inclusion and the condition was considered stable on medical therapy, similar to the 
104 criteria described by Summerfield et al. (2012). 
105
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106 From the patient records, the following data were retrieved: weight, age, gender, 
107 neuter status and echocardiography results. Electrocardiograms and results were 
108 reviewed, if available. Laboratory data (biochemistry and haematology) were 
109 reviewed, where available, to exclude concurrent conditions. Medications and doses 
110 prescribed for each patient were also retrieved.
111 For taurine analysis, heparinised plasma samples were submitted to IDEXX (Referral 
112 assay via IDEXX Laboratories, Wetherby, United Kingdom). Samples were 
113 centrifuged and plasma separated within 30 minutes of the blood sample being 
114 taken. Taurine deficiency was defined as concentrations <50 µmol/L, based on the 
115 laboratory’s reference range interval (50-180 µmol/L); these were extrapolated from 
116 the MUST study (Kittleson et al.,1997) and were also confirmed in others studies that 
117 included various breeds (Kramer et al., 1995; Delaney et al., 2003; Tôrres et al., 
118 2003).
119
120 Doppler Echocardiographic examinations were carried out using a GE Vivid 7 
121 (Buckinghamshire, UK) machine, using a 7S or M4S transducer. The dogs were in 
122 lateral recumbency on a purpose-designed table to allow imaging via the dependent 
123 thoracic wall. Studies have been performed by either a cardiology diplomate or a 
124 cardiology resident under the direct supervision of a diplomate. Two dimensional 
125 (2D) and M-mode images were acquired, recorded and measured according to 
126 standard protocols (Sahn et al. 1978; Thomas et al. 1994; Boon 1998). Data from the 
127 M-mode studies retrieved included left ventricular internal dimensions both in 
128 diastole (LVIDd) and systole (LVIDs); fractional shortening (FS) was calculated. The 
129 M-mode LV diameters were normalised for body weight by allometric scaling in 
130 diastole (LVIDDN) and systole (LVIDSN) (Cornell et al. 2004). The mitral E point to 
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131 septal separation (EPSS) measurement from mitral valve M-mode was also 
132 recorded. From the 2D right parasternal long axis 4 chamber view optimizing the left 
133 ventricular length and area, Simpson’s method of discs was used to determine LV 
134 end-diastolic and end-systolic volumes. Ejection fraction (EF), and sphericity index 
135 were calculated (Dukes-McEwan et al. 2003). The end-systolic and end-diastolic 
136 volumes indexed to body surface area (BSA) were also calculated (LVESVi and 
137 LVEDVi respectively). The BSA was calculated using the standard formula (Ford & 
138 Mazzaferro 2011). Maximal left atrial diameter, measured at the end of ventricular 
139 systole from a right parasternal long-axis 4 chamber view and the short axis ratio of 
140 the left atrium to aortic diameters, measured at the end of diastole, were recorded 
141 (Chetboul & Tissier 2012). Colour flow and spectral Doppler were used to exclude 
142 other significant cardiac diseases. Mitral regurgitation was accepted provided it was 
143 a central jet implying origin due predominantly to stretch of the mitral annulus, rather 
144 than primary mitral valve disease (myxomatous or dysplastic); dogs with markedly 
145 thickened or prolapsing mitral leaflets were not included. Colour flow and spectral 
146 Doppler transvalvular flows were documented, but not analysed further for purposes 
147 of this study.
148 Repeated echocardiographic studies were obtained at a frequency determined by 
149 the attending clinician, and the echocardiographic data were retrieved from every 
150 available examination. 
151
152 Congestive heart failure was defined as left-sided if there were compatible 
153 radiographic findings, when available; in the absence of radiographs, 
154 echocardiographic signs of increased left filling pressures (Schober et al., 2010) in 
155 association with clinical signs and response to furosemide administration were 
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156 considered supportive of CHF. Radiographs had been reviewed and reported by 
157 diagnostic imaging diplomates or diagnostic imaging residents working under 
158 supervision of a diplomate. 
159
160 If dogs had plasma taurine level <50 μmol/L, supplementation with taurine was 
161 commenced. Dogs with CHF or with preclinical DCM were treated according to the 
162 individual clinician and owner preference. Drugs used and their doses were 
163 recorded. 
164
165 Survival time was calculated from the time of initial diagnosis of DCM and taurine 
166 assay to death. Cardiac deaths were defined as sudden death or euthanasia 
167 because of cardiac reasons. Other causes of death were categorised as non-
168 cardiac. Dogs lost to follow-up were censored. 
169
170 Statistical analysis
171 All analyses were performed with Graphpad Prism 7 (GraphPad Software, Inc, La 
172 Jolla, California, US). Data were inspected graphically for normality of distribution 
173 and tested for normality with a Shapiro-Wilk test. Continuous data are presented as 
174 mean ± standard deviation when normally distributed, or as median and interquartile 
175 range (IQR; 25th – 75th percentile) when not normally distributed. 
176
177 Survival time was evaluated for dogs with low and normal taurine levels.  A Kaplan-
178 Meier curve was constructed. Dogs were right censored if still alive, lost to follow-up 
179 or if they had died of non-cardiac disease. 
180
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184 Sixty ECS were evaluated by the cardiology referral service of an academic 
185 institution between 2008 and 2018.
186
187 Forty-four dogs were excluded from the study. Thirty-three of these were diagnosed 
188 with other cardiac diseases. Eleven dogs were excluded due to insufficient data; of 
189 these, 3 dogs were reported to have DCM but no information regarding taurine levels 
190 was available.
191
192 Sixteen dogs met the inclusion criteria: 13/16 had low plasma taurine concentration. 
193 In the dogs with low plasma taurine, the mean taurine concentration was 17.46 ± 
194 11.03 μmol/L. Three dogs had normal taurine concentrations (75, 81 and 194 
195 μmol/L). Thirteen dogs were in congestive heart failure. The 3/16 dogs which did not 
196 have CHF all had low taurine concentrations.
197 The mean age of the dogs included in the study was 6.75 ± 3.02 years, the mean 
198 body weight was 15.3 kg ± 2.7. There were 11 males and 5 females included. There 
199 were 8 males (4 neutered) and 5 females (4 neutered) with low taurine levels. All 
200 dogs with normal taurine levels were males (2 neutered). Signalment, taurine 
201 concentrations, CHF status and medications including taurine supplementation and 
202 outcome at the time of writing are reported for each individual dog in Table 1. 
203 Taurine supplementation was started in all dogs with low taurine concentration at a 
204 dose of 67.8 ± 38.9 mg/kg/day. Eleven dogs did not have taurine levels rechecked, 
205 though the 2 dogs with low taurine levels that did have further measurements 6 
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206 months later showed values of 200 and 279 μmol/L (ref. 50-180). All dogs received 
207 one or more cardiac medications; 8 dogs were receiving other medications or 
208 supplements (Table 1). 
209 Two dogs with low taurine concentrations and one with normal taurine levels 
210 received clopidogrel due to left atrial spontaneous echocontrast, suspected to 
211 represent a hypercoagulable state. The dog with normal taurine also received 
212 doxycycline due to the presence of ticks and the fact that tick-borne disease could 
213 not be ruled-out. The same dog received sildenafil to treat pulmonary hypertension 
214 presumed secondary to left-sided CHF. Another dog with low taurine levels received 
215 amlodipine in the attempt of afterload reduction.
216
217 Echocardiographic variables at admission and at follow-up (median 30 days; range 
218 7-90) were reported (Table 2). Serial echocardiographic studies were available for 
219 10/16 dogs. Comparison between echocardiographic variables at baseline and at the 
220 first follow-up are shown (Fig. 1). Figure 2 shows echocardiographic images of one 
221 of the dogs with low taurine concentration with dilated left ventricle and poor systolic 
222 function before (Fig. 2a-2b) and after (Fig. 2c-2d) taurine supplementation; is 
223 improvement of left ventricular dimensions and systolic function at the recheck 
224 although statistical comparison was not performed (Before: EF: 38%; FS: 11%; 
225 LVESVi: 102.9 mL/m2; LVIDSN: 2.07; LVIDDN: 2.47. After: EF: 47%; FS: 7%; 
226 LVESVi: 64.2 mL/m2; LVIDSN: 1.07; LVIDDN: 1.93). In all dogs included in the 
227 study, there was a subjective improvement between admission and first re-check 
228 values of LVESVi, LVIDSN, LVIDDN and EF. The dogs with low taurine levels 
229 showed a subjective improvement between admission and re-check values of 
230 LVIDSN and LVIDDN, but not in LVESVi and EF. Again, all the above values were 
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231 not statistically compared due to low numbers and to avoid “testing against 
232 baseline”. For the dogs which underwent serial echocardiographic examinations, 
233 graphical representation of LVESVi and LVIDSN values over time are shown in 
234 figures 3a and 3b, respectively (Fig. 3a-b).
235  
236 All dogs that died before the end of the study were euthanized due to worsening of 
237 their cardiac disease (Table 1). Four dogs were lost to follow-up (all had low taurine 
238 concentrations, 3 were in CHF).
239 The median survival time (MST) for all dogs included in the study was 1155 days 
240 (195 -2800) (Fig. 4). Dogs with low taurine levels had a MST of 2800 days (790 – 
241 upper limit not calculable), whereas those with normal levels had a survival time of 
242 14, 90 and 478 days. The 13 dogs in with CHF (10 with low taurine levels and 3 with 
243 normal levels) had a MST of 1155 days (478-2800), whereas the two non-CHF dogs 




248 Based on our laboratory reference range, we found that taurine deficiency is 
249 commonly identified in ECS diagnosed with DCM. However, no clear causal 
250 association could be identified in this study; indeed, the study design does not allow 
251 causal relationships to be investigated. 
252 The serial echocardiographic data shows that taurine supplementation might not be 
253 curative and taurine deficiency may not be the sole cause of DCM phenotype in this 
254 breed. In dogs with serial echocardiographic data, we did not carry out any statistical 
255 analysis in view of small numbers in this descriptive study. However, data suggest 
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256 that taurine supplementation might not be curative and taurine deficiency may not be 
257 the sole cause of DCM phenotype in this breed. This has also been shown in other 
258 breeds such as ACS, Golden retrievers, Newfoundlands and Irish Wolfhounds 
259 (Kittleson et al. 1997; Fascetti et al. 2003; Alroy et al. 2005; Bélanger et al. 2005; 
260 Backus et al. 2006; Vollmar et al. 2013). In contrast, cats with taurine-deficientcy 
261 DCM have a reversible cardiomyopathy with taurine supplementation (Pion et al. 
262 1987). 
263 We did not measure the whole blood taurine concentrations and these have been 
264 reported to be substantially higher than plasma taurine concentrations (Delaney et 
265 al., 2003). Whole blood taurine concentration may be superior, if available, as it more 
266 closely reflects muscle taurine concentration and therefore overall taurine status, 
267 whereas plasma taurine may reflect fasting or post-prandial status (Delaney et al 
268 2003).  For this study, only plasma taurine concentrations could be assayed and no 
269 record were made of when each dog’s last meal had been taken prior to sampling. 
270
271 As mentioned above, no statistical analysis was performed between admission and 
272 re-check echocardiography values in order to avoid “testing against baseline”, 
273 therefore only subjective or visual assessments could be made; however, it is 
274 interesting to notice changes that we recorded in our dogs during the study period. 
275 As figures 1 a-h and 3 a-b show, at the first follow-up echocardiography values 
276 showed reduction in LV diameter and volumes (LVIDd, LVESVi, LVIDDN, LVIDSN) 
277 with improved systolic function (EF, LVESVi) if the whole population was considered. 
278 However, those with low taurine levels at the re-check, had an improvement in 
279 LVIDd, LVIDDN and LVIDSN but not in LVESVi and EF. In line with our data, 
280 Kittleson and colleagues (1997) reported that ACS with DCM and low taurine 
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281 concentrations showed improved systolic function after supplementation. Taurine 
282 supplementation may improve systolic function, even in the absence of a taurine 
283 deficient state as shown in. In a study conducted in people with chronic CHF, where 
284 taurine supplementation was given for 6 weeks and a substantial improvement in 
285 systolic function was reported (Azuma et al. 1992).  Therefore, it is possible that 
286 taurine supplementation at pharmacological doses, could have played a role in the 
287 reduction of the LV chamber dimensions and improvement in systolic function in our 
288 population of ECS, even if low-taurine status was not associated with their DCM. 
289 Since all ECSs also received conventional cardiac therapy, it is not possible to 
290 separate the effects of this medications from taurine supplementation in ECS with 
291 low taurine concentrations. Diuretics reduce preload, which will reduce LV size 
292 (showed by a reduction in values of LVIDd), as well as resolving fluid retention 
293 associated with CHF due to both systolic dysfunction and RAAS activation. It is also 
294 well documented that pimobendan reduces ventricular size in both CHF and 
295 preclinical DCM patients as well as dogs with mitral valve myxomatous disease 
296 (Summerfield et al. 2012; Häggström et al. 2013; Boswood et al. 2016).
297
298 A relationship between taurine deficiency and DCM phenotype in ACS was initially 
299 reported by Kramer et al. (1995). A few years later, in the multicentred spaniel trial 
300 (MUST) study, Kittleson and colleagues (1997) showed an improved systolic function 
301 in the breed following supplementation with both taurine and L-carnitine. 
302 Unfortunately, the concurrent use of both supplements makes it unclear whether the 
303 response observed was due to the concurrent L-carnitine supplementation. In our 
304 study, myocardial L-carnitine levels were not assessed, as myocardial biopsies are 
305 required for diagnosing carnitine deficiency (Meurs, 2004) and L-carnitine was only 
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306 supplemented in one dog (dog 4 in Table 1), who died a cardiac death 115 days 
307 after diagnosis without a follow-up echocardiography. It is therefore possible that 
308 different results may had been achieved if L-carnitine was also routinely 
309 supplemented to the low taurine dogs, which would then also allow a direct 
310 comparison with the MUST study (Kittleson et al 1997). Indeed, one of the reasons 
311 why L-carnitine was started in the MUST study population was because the first 2 
312 ACS failed to reach demonstrable improvement with taurine alone, despite normal 
313 plasma levels of L-carnitine (Kittleson et al 1997). Taurine synthesis has also been 
314 shown to differ between breeds, with large breeds more predisposed to deficiency: 
315 groups of Newfoundlands and Golden Retrievers have been reported to have low 
316 taurine concentration and a DCM phenotype, which improved after taurine 
317 supplementation (Fascetti et al. 2003; Bélanger et al.2005; Backus et al. 2006).
318 In cats, taurine deficiency can be associated with several potential causes including 
319 increased excretion with urine and faeces (Hickman et al., 1992; Edgar et al. 1998). 
320 In our study, urinary and faecal taurine concentration were not measured. Another 
321 explanation for taurine deficiency is related to diet. C and consumption of certain 
322 commercial and prescription diets have been implicated with low plasma taurine 
323 concentrations in dogs with DCM (Sanderson et al. 2001; Fascetti et al. 2003; 
324 Sanderson, 2006; Ko et al. 2007; Kaplan et al. 2018).
325 More recently, grain free diets and exotic ingredients have been suspected to be 
326 associated with DCM phenotype (Freeman et al. 2018) although not always with low 
327 taurine concentrations. Unfortunately, we were unable to retrieve diet history for all 
328 the ECS due to the retrospective nature and long time-course of our study.
329
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330 Two dogs with low taurine levels and one with normal taurine levels received 
331 clopidogrel due to the presence of left atrial spontaneous echocontrast. This can also 
332 be associated with low velocity blood flow or inflammatory disease and both 
333 conditions can lead to thrombus formation. (Spence et al., 2019)
334
335 In this study, ECS affected by DCM and CHF had a MST of 1155 days. This which is 
336 much longer than the survival time associated with DCM and CHF reported in the 
337 literatureother breeds. A survival time of 27 days was reported in 189 dogs of various 
338 breeds with DCM and CHF whereas a MST of 65 days was found in a group of 37 
339 dogs affected by DCM; in both these studies, dogs did not receive pimobendan 
340 (Monnet et al. 1995; Tidholm et al. 1997). 
341 More recent data showed a MST of 133 days in 369 dogs of various breeds with 
342 DCM (74% in CHF at presentation) (Martin et al.,2009). Dobermanns in CHF were 
343 also shown to have a short MST of 50.67 days that increased to 329 days with 
344 pimobendan therapy (Luis Fuentes et al., 2002). Dobermanns with preclinical DCM 
345 at presentation had times to primary end-point (sudden death or CHF) of 441 days 
346 which was shown to increase to 718 days in dogs receiving pimobendan 
347 (Summerfield et al. 2012). American Cocker Spaniels with DCM and low-taurine in 
348 the MUST study (Kittleson et al. 1997) had a longer MST (849 days) than that 
349 reported in previous studies, but still shorter than our ECS. Data from an 
350 unpublished study state a MST of ECS with DCM of 750 days (P. Wotton, 1998)1; 
351 however, taurine levels were not measured in these dogs, nor was it supplemented. 
352 In the study by Luis Fuentes (2002), ECS receiving placebo or pimobendan had a 
1 Wotton, P.R., (1998). Cardiomyopathy in English cocker and springer spaniels: A review of 38 cases. 
Proceedings of the British Small Animal Veterinary Association, p.316.
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353 MST of 537 and 1037 days, respectively, showing considerably longer survival time 
354 compared to other breeds, which is supported by the results presented here. The 
355 most recent comparison of different breeds with DCM showed ECS with DCM to 
356 have a MST of 511 days, the longest amongst all the breeds in the study (Pedro et 
357 al. 2011). It can be appreciated from these studies that the MST may be longer in 
358 ECS, compared with other breeds with DCM. 
359 The MST of the dogs with low taurine levels was 2800 days, numerically longer than 
360 that reported for ECS with DCM in other publications (511 days, Pedro et al 2011; 
361 750 days, Wotton 1998, unpublished data). Dogs from Dr Wotton’s historical study 
362 did not receive pimobendan, which might explain the shorter MST. Dobermanns with 
363 DCM receiving pimobendan showed a longer MST than those on placebo, but the 
364 same study did not show a statistically significant improvement in ECS receiving 
365 pimobendan., perhaps This may be because they survived for longer regardless of 
366 treatment, provided the CHF was controlled (Luis Fuentes et al. 2002). Nevertheless, 
367 oOur results may suggest a response to taurine supplementation, however this was 
368 only a subjective improvement in a small population in which it was not appropriate 
369 to make statistical comparison.
370 It is possible that once CHF is well managed, ECS may have a more favourable 
371 prognosis despite the diagnosis of DCM., although T the low numbers of dogs in the 
372 pre-clinical phase may have affected these results. 
373
374 Statistical comparison of MST of dogs in CHF and not in CHF, dogs with low taurine 
375 levels and normal taurine levels was not performed due to low numbers that would 
376 have led to unreliable results.
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380 This study has some limitations due to its retrospective nature. Firstly, we had a 
381 small number of cases and this could have affected the reliability of the results. The 
382 low numbers of ECS with DCM with normal taurine concentration mean it was not 
383 possible to compare aspects about DCM or response to treatment in these dogs and 
384 the dogs with low taurine concentrations. 
385 We did not compare echocardiographic values between baseline and recheck to 
386 avoid “testing against baseline”, therefore, the above results should be considered 
387 as subjective based on visual assessments of the graphs. The echocardiographic 
388 examinations were performed by different operators and inter-operator and inter-
389 observer variability were not assessed as part of this study. However, all 
390 echocardiographers had undergone similar training and followed similar acquisition 
391 and measurement protocols. 
392 Histopathology was not performed in any of the cases included in the study, 
393 therefore, the diagnosis was based on echocardiographic findings. We also did not 
394 obtain pedigree information from these dogs, so we were not able to investigate for 
395 familial DCM, or possible inherited basis for the taurine deficiency. This should be 
396 addressed in future prospective studies. 
397 Dogs were classified as taurine deficient based on the laboratory reference interval.  
398 but Bbreed specific reference range is currently not available. Ideally, taurine 
399 concentration should have been tested in a control group of ECS without DCM since 
400 it is possible that this breed has different basal plasma taurine levels as 
Page 17 of 34
Journal of Small Animal Practice
Journal of Small Animal Practice
Review Copy
401 demonstrated in Golden Retrievers (Ontiveros et al., 2020). Also, whole blood 
402 taurine concentrations were not measured in this study.
403 We did not investigate the type of diet the dogs were fed so we cannot assess the 
404 association between diet and DCM in this study (Freeman et al., 2018).
405 Taurine plasma concentrations after supplementation were not measured in most 
406 dogs, therefore the effectiveness of supplementation cannot be confirmed. However, 
407 in those with taurine concentrations rechecked after supplementation, increased 
408 taurine values were recorded. Moreover, in the MUST study (Kittleson et al. 1997), 
409 all ACS had increased taurine concentrations with similar dose of supplementation 
410 as in our study. Furthermore, a study in Newfoundlands showed that taurine 
411 supplementation at any dose normalised blood taurine levels and higher doses were 
412 associated with increased urinary taurine loss and no changes in plasma or whole 
413 blood taurine concentrations (Dukes-McEwan et al., 2001).
414 MoreoverAn additional limitation was that plasma or myocardial carnitine 
415 concentrations were not measured and supplementation was started in only one dog 
416 making direct comparison with the MUST study impossible. 
417 We were unable to determine if the improvements in echocardiographic variables 
418 were secondary to the taurine supplementation or due to the other standard cardiac 
419 medications; treating dogs with only taurine supplementation would be ethically 
420 unacceptable. Moreover, the treatment of dogs was not standardized, although most 
421 of the patients were receiving similar medications for CHF. The dogs with normal 
422 taurine concentrations (3) were in CHF and this could affect the survival analysis 
423 leading to a longer MST for dogs with low taurine concentration (10/13 in CHF). We 
424 did not have a MST value for the non-CHF dogs due to the high number of censored 
425 cases (1 out of 3).
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426 Two dogs were receiving diltiazem to treat supraventricular tachycardias. This could 
427 have affected the survival analysis. Tachycardiomyopathy was possible though 
428 considered less likely since the arrhythmia was diagnosed after the diagnosis of 
429 dilated cardiomyopathy; therefore was believed to be secondary to atrial stretch.” 
430 Lastly, one dog had treated hypothyroidism, with historical low serum total thyroxine 
431 (T4) concentrations. This dog was not excluded from the study since this condition 
432 was considered stable and the dog had been treated with levothyroxine for 4 months 




437 In conclusion, this study has revealed that taurine deficiency is common in ECS 
438 affected by DCM; taurine status should be checked in this breed if a diagnosis of 
439 DCM is made. Based on the current study, a direct association between these two 
440 conditions could not be established but it is suspected. We provided further evidence 
441 that ECS have a longer survival time than other breeds with DCM, especially those 
442 with taurine deficiency who are supplemented. 
443
444 A larger prospective study is needed to confirm the incidence of taurine deficiency in 
445 ECS and its association with DCM. The role of supplementing L-carnitine 
446 concurrently should also be explored. In particular, including a detailed diet history in 
447 prospective assessments will be essential.  
448
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620 Figures
621 Fig. 1 Line chart of the echocardiographic values at admission and at the first 
622 recheck. Only dogs with available echocardiographic values are shown. The dogs 
623 with normal taurine levels are indicated with red dots. The horizontal line is the mean 
624 value. 
625 1a) LVESVi: left ventricular end-systolic volume indexed to body surface area. 1b) 
626 LVEDVi: left ventricular end-diastolic volume indexes to body surface area. 1c) 
627 LVIDDN: left ventricular internal dimension in diastole normalized for body weight. 
628 1d) LVIDSN: left ventricular internal diameter in systole normalized for body weight. 
629 1e) EF: ejection fraction. 1f) FS: fractional shortening. 1g) LVIDd: left ventricular 
630 internal dimension in diastole. 1h) EPSS: Mitral M-mode E-point septal separation. 
631
632 Fig 2a Echocardiographic 2D image of one of the dogs with low taurine 
633 concentration before starting supplementation. Right parasternal long-axis 4-
634 chambers view showing severe left ventricle dilation. EF: 36%. Fig 2b 
635 Echocardiographic M-Mode image of one of the dogs with low taurine concentration 
636 before starting supplementation. Right parasternal short-axis view at the level of the 
637 papillary muscles showing poor systolic function and dilated left ventricle. FS: 11%; 
638 LVESVi: 102.9 mL/m2; LVIDSN: 2.07; LVIDDN: 2.47. Fig 2c Echocardiographic 2D 
639 image of one of the dogs with low taurine concentration after starting 
640 supplementation (3 months). Right parasternal long-axis 4-chambers view showing 
641 less severe left ventricle dilation. EF: 47%. Fig 2d Echocardiographic M-Mode image 
642 of one of the dogs with low taurine concentration after starting supplementation (3 
643 months). Right parasternal short-axis view at the level of the papillary muscles 
644 showing improved systolic function and left ventricular dimensions. FS: 7%; LVESVi: 
645 64.2 mL/m2; LVIDSN: 1.07; LVIDDN: 1.93.
646 Abbreviations: EF: ejection fraction. FS: fractional shortening. LVESVi: left 
647 ventricular end-systolic volume indexed to body surface area. LVIDSN: left 
648 ventricular internal diameter in systole normalized for body weight. LVIDDN: left 
649 ventricular internal diameter in diastole normalized for body weight.
650
651 Fig. 3a Graphic representation of the left ventricular end-systolic volume indexed to 
652 body surface area of all dogs with echocardiographic follow-up values. Fig. 3b 
653 Graphic representation of the left ventricular internal dimension in systole normalized 
654 for body weight of all dogs with echocardiographic follow-up values. 
655 Red dots indicate dogs with normal taurine levels. Each dot indicates an 
656 echocardiographic examination.
657 Abbreviations: LVESVi: left ventricular end-systolic volume indexed to body surface 
658 area. LVIDSN: left ventricular internal diameter in systole normalized for body 
659 weight. 
660
661 Fig. 4 Kaplan Meier survival curve of the entire population of dogs included in the 
662 study.
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LTC 10 M 15 27






8 FN 11.7 19




LTC 9 ME 14.7 19
0.3 66
Diltiazem






2 ME 18.9 15 279






11 MN 13.5 75
0.8 9 1.2 0.4 80
Hydrochlorthiazide






9 MN 13.6 194










7 ME 16.5 81
0.5 5 2.3 0.3 90 Alive
910
Dog n° 14 had taurine concentrations close to the lower reference interval and was supplemented. Dog n° 4 received carnitine despite lack of concentration measurements. 
Abbreviations: ME: male entire. MN: male neutered. FE: female entire. FN: female neutered. LTC: low taurine concentration. NTC: normal-taurine concentration. CHF: congestive 
heart failure. 
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Table 2. Mean echocardiographic values of the dogs included in the study at admission and at the first recheck after admission; subdivided in all 
population, LTC and NTC. 
ALL POPULATION Variables at admission: mean (± standard deviation; SD) First recheck after admission: mean (± SD) 
LVIDd (mm) 51.55 (± 9.6) 49.92 (± 10.6)
LVIDDN 2.32 (± 0.45) 2.26 (± 0.53)
LVIDSN 1.88 (± 0.39) 1.68 (± 0.37)
LVESVi (mLs/m2) 107.9 (± 38.8) 94.4 (± 39.0)
LVEDVi (mLs/m2) 153.9 (± 60.78) 152.9 (± 66.38)
Ejection fraction (%) 27.4 (± 10.6) 34.1 (± 11.89)
Fractional shortening (%) 14.89 (± 5.94) 16.62 (± 7.43)
EPSS (mm) 15.5 (± 5.1) 14.5 (± 5.0)
LTC
LVIDd (mm) 49.69 (± 8.7) 46.67 (± 6.5)
LVIDDN 2.22 (± 0.38) 2.06 (± 0.37)
LVIDSN 1.77 (± 0.35) 1.63 (± 0.40)
LVESVi (mLs/m2) 104.8 (± 40.8) 95.4 (± 41.8)
LVEDVi (mLs/m2) 148 (± 63.1) 140 (± 69.1)
Ejection fraction (%) 28.1 (± 11.4) 34.1 (± 13.2)
Fractional shortening (%) 14.87 % (± 6.37) 16.28 (± 7.31)
EPSS (mm) 14.4 (± 5.0) 11.8 (± 4.5)
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NTC (individual values)
LVIDd (mm) 56.6 / 68.8 / 53.2 56.4 / 47.6
LVIDDN 2.63 / 3.19 / 2.33 2.71 / 2
LVIDSN 2.06 / 2.64 / 2.01 2.05 / 1.64
LVESVi (mLs/m2) 107.8 / 156.4 / 100.2 117.3 / 64.1
LVEDVi (mLs/m2) 156.4 / 215.7 192.9
Ejection fraction (%) 30 / 26.8 / 16.6 38.5 / 29.8
Fractional shortening (%) 17 / 13 / 9 20 / 13
EPSS (mm) 2.05 / 2.07 / 1.21 1.68 / 1.77
At the recheck 5 dogs in the LTC did not have values available. 
Abbreviations: LTC: low taurine concentration. NTC: normal-taurine concentration. LVIDd: left ventricular internal diameter in diastole. LVIDDN: left 
ventricular internal diameter in diastole normalized for body weight. LVIDSN: left ventricular internal diameter in systole normalized for body 
weight. LVESVi: left ventricular end-systolic volume indexed to body surface area. LVEDVi: left ventricular end-diastolic volume indexed to body 
surface area. EPSS: Mitral M-mode E-point septal separation. NA not applicable.
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